Mechanical Thrombectomy Market Analysis | Europe | 2017-2023 | MedCore

Mechanical Thrombectomy Market Analysis | Europe | 2017-2023 | MedCore

0

Ischemic Stroke is caused by an obstruction within a blood vessel that is supplying blood to the brain. This is often caused by blood clots but can also be caused by other substances like plaques. The gold standard treatment for strokes for many years has been the administration of clot dissolving or clot busting medication called tissue plasminogen activator (tPA). This type of drug must be administered as soon as possible, with a four hour window from symptom onset, to increase chances of recovery. A significant number of patients do not get to healthcare facilities quickly enough to meet that window and even some of those who do, later experience hemorrhagic complications from the medication. It is very effective for smaller clots but often fails to break up larger clots. Some patients cannot receive tPA, in which cases physicians rely on antiplatelet or anticoagulant medicine to ensure blood clots do not get larger.

  • Year: 2017
  • Scope: 2013-2023
  • Region: Europe
  • Published Date: 12/1/2016
  • Pages: 268
  • Type: MedCore

There will be significant market growth in the mechanical thrombectomy market over the forecast period, driven by growth in unit sales as mechanical thrombectomy is adopted as standard of care for acute ischemic stroke patients.

In recent years, new innovative treatment options have entered the market. Studies have shown that patients who receive intravenous tPA in conjunction with endovascular therapy have significantly improved clinical outcomes versus those who only receive tPA. The initial device involved a wired-caged device called a stent retriever that was inserted into the patient’s body endovascularly and maneuvered to the blocked blood vessel to grab the clot.

Segments Covered in This Market

  • Thrombectomy Catheter Market
  • Stent Retriever Market

Report Data Types Included

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • 10 Year Scope (3 Year Historical + 7 Year Forecast Period)
  • Market Drivers & Limiters for Each Segment
  • Competitive Analysis with Market Shares
  • Product Portfolios
  • Related Press Releases from Top Competitors

Companies Analyzed

Of the many companies in the European Mechanical Thrombectomy market, Penumbra was the leader, followed by Medtronic and Stryker. Penumbra had their first aspiration system CE marked in 2006 and commercially available in Europe since June, 2007 when it was deemed equivalent to other thrombectomy devices on the market. In December 2014 the Penumbra System ACETM 64 received its CE mark. Other companies in this segment include Phenox, Codman Neuro, Acandis, and Neurvi.

About Our In-Depth MedCore Research

Our analysts meticulously research for up to 3 to 4 months to put together one suite of reports (MedSuite), which is a comprehensive analysis on a group of healthcare markets. A MedCore is one portion of that analysis that focuses on one market segment, and provides further detailed segmentation to get a much more granular set of market data.

This MedCore is also found in the full report suite titled Europe Market Report Suite for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices – MedSuite

Learn More about these product types



The "Europe Market Report Suite for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices 2017 - MedSuite" includes analysis on the following companies currently active in this market:
Medtronic
Stryker
Codman & Shurtleff, Inc.
St. Jude Medical
Nevro
Carl Zeiss
Boston Scientific
LivaNova
Terumo MicroVention
Penumbra Inc.
Leica
Integra LifeSciences
BrainLab
Balt
Magstim
Phenox
MagVenture
Elekta
Moëller Wedel
Misonix
Sophysa
Aesculap
MAG & More
Neurosoft
Acandis
Soring
Brainsway
Nexstim
Others include: ANT, Asahi Intecc, Axonics, Blockade, Dispomedica, Enteromedics, Flowonix, Inomed, Intrapace, Kaneka Medical Products, MHT, Micrus Endovascular, MRC, Navimetric, Neuravi, Neuronetics, Neuropace, NextGen Medicla System, Nuvectra, Scientia Vascular, Spiegelberg, Stimwave, Tokai Medical Product, Tricumed, Vascular Solutions, etc.
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.




iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology


close-link
close-link

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers

close-link
close-link
close-link
close-link